Literature DB >> 8180781

p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos.

B G Schneider1, S G Hilsenbeck, C H Hensel, V Pekkel, C H Shelton, H A Rodríguez-Martínez, M E Gutiérrez-Díaz, D R Pulitzer, D C Allred.   

Abstract

Gastric cancer is more than twice as common in Hispanics as in Anglos in Texas, while colorectal cancer is almost twice as common in Anglos as Hispanics. To test the hypothesis that mutations in the p53 tumour suppressor gene are involved in these differences, we examined 131 gastric and 138 colorectal cancers from Hispanic and Anglo patients from South Texas and Mexico using immunohistochemistry (IHC) as a screening assay for p53 mutations. The fraction of p53 positive cases was not significantly different in gastric cancers from Hispanics compared to Anglos (43% versus 61%, respectively, p = 0.13) or in colorectal cancer (57% versus 58%, respectively, p = 1.0), suggesting that p53 mutations are not involved in causing the different incidences of these cancers in these populations. In addition, the types of p53 mutations arising in gastric tumours from Hispanic patients were consistent with those reported in gastric tumours in other populations. Sequencing of mutations in five gastric cancers revealed two G:C to A:T transitions, two A:T to G:C transitions and one complex deletion. In contrast with findings in studies in other tumour types, neither stage nor survival was associated with p53 positive staining by IHC in either gastric or colorectal tumours in this study. Positive p53 immunostaining was associated with the diffuse histological subtype in gastric carcinoma (p = 0.05) and high histological grade in colorectal carcinoma (p = 0.04).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8180781     DOI: 10.1007/bf00193499

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  52 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

2.  Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer.

Authors:  C H Hensel; R H Xiang; A Y Sakaguchi; S L Naylor
Journal:  Oncogene       Date:  1991-06       Impact factor: 9.867

3.  Estimates of the worldwide frequency of sixteen major cancers in 1980.

Authors:  D M Parkin; E Läärä; C S Muir
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

4.  Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines.

Authors:  J H Kim; T Takahashi; I Chiba; J G Park; M J Birrer; J K Roh; H De Lee; J P Kim; J D Minna; A F Gazdar
Journal:  J Natl Cancer Inst       Date:  1991-07-03       Impact factor: 13.506

Review 5.  5-Methylcytosine in eukaryotic DNA.

Authors:  M Ehrlich; R Y Wang
Journal:  Science       Date:  1981-06-19       Impact factor: 47.728

6.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

7.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

8.  Frequent p53 mutations in head and neck cancer.

Authors:  K D Somers; M A Merrick; M E Lopez; L S Incognito; G L Schechter; G Casey
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

9.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Authors:  A D Thor; I I Moore DH; S M Edgerton; E S Kawasaki; E Reihsaus; H T Lynch; J N Marcus; L Schwartz; L C Chen; B H Mayall
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

10.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Authors:  A S Sarkis; G Dalbagni; C Cordon-Cardo; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal:  J Natl Cancer Inst       Date:  1993-01-06       Impact factor: 13.506

View more
  7 in total

1.  Higher expression of oncoproteins c-myc, c-erb B-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors.

Authors:  J L Yang; K T Ow; P J Russell; J M Ham; P J Crowe
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

2.  Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma.

Authors:  M Salih Deveci; Güzin Deveci
Journal:  Gastric Cancer       Date:  2007-06-25       Impact factor: 7.370

3.  The health attitudes of young Hispanic women and the health status of their children on the Texas-Mexico border.

Authors:  A Y Russell; M S Williams; P A Farr; A J Schwab; S Plattsmier
Journal:  J Community Health       Date:  1998-06

4.  Prognostic significance of Bcl-2 and p53 expression in gastric cancer.

Authors:  Hyeon Kook Lee; Hye Seung Lee; Han-Kwang Yang; Woo Ho Kim; Kuhn Uk Lee; Kuk Jin Choe; Jin-Pok Kim
Journal:  Int J Colorectal Dis       Date:  2003-06-13       Impact factor: 2.571

5.  Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies.

Authors:  José Cangiano; Barbara A Centeno; Christopher R Garrett; William Cáceres; Ana de Jesús; Ji-Hyun Lee; Orestes Pavía; Richard Jove; Luis Báez; Daniel M Sullivan; Carlos A Muro-Cacho; Teresita Muñoz-Antonia
Journal:  Dig Dis Sci       Date:  2008-01-26       Impact factor: 3.199

6.  Frequency and spectrum of p53 mutations in gastric cancer--a molecular genetic and immunohistochemical study.

Authors:  C Poremba; D W Yandell; Q Huang; J B Little; W Mellin; K W Schmid; W Böcker; B Dockhorn-Dworniczak
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Clinicopathological significance of E-cadherin, β-catenin and p53 expression in gastric adenocarinoma.

Authors:  Mohammad Reza Zali; Omeed Moaven; Hamid Asadzadeh Aghdaee; Kamran Ghafarzadegan; Khadijeh Jami Ahmadi; Mehdi Farzadnia; Azadeh Arabi; Mohammad Reza Abbaszadegan
Journal:  J Res Med Sci       Date:  2009-07       Impact factor: 1.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.